Novartis AG

Walking into aging: real-world mobility patterns and digital benchmarks from the InCHIANTI Study (2025) Albites-Sanabria J, Palumbo P, Bandinelli S, D’Ascanio I, Mellone S, Paraschiv-Ionescu A, Küderle A, et al. Journal article Benchmarking vision-language models for diagnostics in emergency and critical care settings (2025) Kurz CF, Merzhevich T, Eskofier B, Kather JN, Gmeiner B Journal article Evaluating the Divide Between Patients’ and Physicians’ Perceptions of Adult-Onset Still’s Disease Cases: Insights from the PRO-AOSD Survey (2025) Blank N, Andreica I, Rech J, Sözen Z, Feist E Journal article CD40 blockade hampers IgG class-switch while enhancing Granzyme B production by transitional B cells (2025) Werner F, Wittner J, Lehmann C, Wahlbuhl-Becker M, Allabauer I, Hoffmann A, Schnell A, et al. Journal article Machine Learning Predictions of Overall and Progression-Free Survival in Advanced Breast Cancer (2025) Merzhevich T, Tanzanakis A, Salin E, Quiering C, Kurz C, Gmeiner B, Eskofier B Conference contribution Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial (2025) Pavel ME, Caplin ME, Ruszniewski P, Hertelendi M, Krenning EP, Strosberg JR Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article